Clinical, molecular and functional biomarkers for PROgnosis, pathomechanisms and treatment strategies of COVID-19 (PROVID) - (PROVID-PROGRESS)

• Conditions: U07.1; J12; J13; J14; J15; J16; J17; J18; COVID-19, virus identified; Viral pneumonia, not elsewhere classified

• Registration Number: DRKS00023277
• Lead Sponsor: Charité – Universitätsmedizin Berlin, Med. Klinik m. S. Infektiologie und Pneumologie, und Arbeitsbereich Pulmonale Inflammation

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-11-09
• Last Update Posted: 19 August 2024

Recruitment & Eligibility

• Status: Complete
• Sex: All
• Target Recruitment: 94

Inclusion Criteria

Positive detection of SARS-CoV-2-virus, Informed consent signed

Exclusion Criteria

Patient participation in PROVID-CAPNETZ, PROVID-PROGRESS or PROVID-CAPSyS at an earlier time, simultaneous participation in PROVID-CAPNETZ, pregnancy, breast feeding period, active tuberculosis

Study & Design

• Study Type: observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Severe course of disease (Necessity of treatment on intensive care unit or death).

Secondary Outcome Measures

Name	Time	Method
ength of hospitalization<br>length of ICU treatment<br>length of mechanical ventilation<br>organ involvement (complications)<br>long-term effects<br>changes in quality of life<br><br> <br>